Obsidian Therapeutics, Inc.
No enriched coverage for $OBX in the last 7 days.
No SEC Form 4 filings for $OBX in the last 30 days.
See all $OBX insider activity →Obsidian Therapeutics, Inc. (OBX) filed an IPO registration statement for up to 29,164,045 shares of common stock, but this is a resale registration by selling stockholders, not a company sale. The company will not receive proceeds from these resales. Obsidian's common stock began trading on Nasdaq under the symbol 'OBX' on August 4, 2026, with a closing price of $17.04 per share on August 27, 2026.
Obsidian Therapeutics (OBX) shares rose 16.36% to $32.00 after the company enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study for amsoki-cel (OBX-115) in checkpoint inhibitor-resistant advanced melanoma. Obsidian also completed a $350 million private placement, expecting cash to fund operations into 2H 2028.
24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
Recent OBX coverage spans financial news, ipo and technology.
The filing introduces new share supply potential but no immediate proceeds, likely creating modest upside volatility.
Enrollment progress plus prior response-rate results and a large cash raise support a near-term momentum bid, while pushing key readout risk into 2027.
Buy initiation can still shift sentiment, but lack of target reduces precision.
Positive initiation can boost sentiment for biotech risk-on positioning.
Reverse-merger listing plus fresh capital is a near-term liquidity and valuation catalyst for OBX, with funding runway into 2H 2028.
alphai scores every news story that mentions OBX with an AI model for sentiment and relevance, and aggregates insider trades from Obsidian Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Obsidian Therapeutics, Inc. (OBX) filed an IPO registration statement for up to 29,164,045 shares of common stock, but this is a resale registration by selling stockholders, not a company sale. The company will not receive proceeds from these resales. Obsidian's common stock began trading on Nasdaq under the symbol 'OBX' on August 4, 2026, with a closing price of $17.04 per share on August 27, 2026.
2 min readObsidian Therapeutics (OBX) shares rose 16.36% to $32.00 after the company enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study for amsoki-cel (OBX-115) in checkpoint inhibitor-resistant advanced melanoma. Obsidian also completed a $350 million private placement, expecting cash to fund operations into 2H 2028.
3 min read24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
4 min readAnalyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
7 min readRTW Biotech Opportunities said Obsidian Therapeutics completed its merger with Galera Therapeutics Inc. via a reverse merger, with a concurrent private financing of about $350m. The combined company began trading on Nasdaq as Obsidian Therapeutics under ticker OBX on 4 Aug 2026. Proceeds are expected to fund operations into H2 2028.
3 min readObsidian Therapeutics, Inc. (OBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of
6 min read
